Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865677 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT06865677: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT06865677 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06865677, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers. Researchers want to see if SG can also help people with ovarian, endometrial, or cervical cancers. Objective: To test SG in people with ovarian, endometrial, or cervical cancers. Eligibility: People aged 18 years and older with ovarian, endometrial, or cervical cancer. Their cancers must have returned after at least 2 rounds of standard treatments. Design: Participants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. They also will have biopsies to get new tissues samples taken from their tumors. SG is infused through a tube attached to a needle inserted into a vein in the arm. Treatment will be given in 21-day cycles. Participants will receive SG on days 1 and 8 of each cycle. Each infusion takes 1 to 3 hours. Participants may receive SG for up to 5 years. They can continue as long as the drug is helping them. Imaging scans and other tests will be repeated throughout the study period. Participants will have an end-of-treatment visit within 2 weeks and a safety visit about 30 days after they stop treatment. Physical exams, blood tests, and imaging scans may be repeated. Participants will then be contacted by phone every 6 months for up to 10 years after their first dose of SG. Sponsoring Institution: National Cancer Institute...
Interventions
- DRUG Sacituzumab Govitecan
- DIAGNOSTIC_TEST Brain MRI
- PROCEDURE Tumor biopsy
- DIAGNOSTIC_TEST CT scans
- DIAGNOSTIC_TEST EKG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865677
The ClinicalTrials.gov registry entry for NCT06865677 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sacituzumab Govitecan is the first listed.
NCT06865677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06865677 about?
NCT06865677 is a clinical study titled "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas". Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers. Researchers want to see if SG can also help people with ovarian, endometrial, or cervical cancers. Objective: To tes...
What is the current status of trial NCT06865677?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2025-06-09. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06865677?
The interventions under investigation include: Sacituzumab Govitecan (DRUG), Brain MRI (DIAGNOSTIC_TEST), Tumor biopsy (PROCEDURE), CT scans (DIAGNOSTIC_TEST), EKG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06865677?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.